![]() |
市场调查报告书
商品编码
2008729
PET-CT扫描仪设备市场报告:按类型、切片数量、同位素/检测器类型、服务供应商、应用和地区划分,2026-2034年PET-CT Scanner Device Market Report by Type, Slice Count, Isotope and Detector Type, Service Provider, Application, and Region 2026-2034 |
||||||
2025年全球PET-CT扫描仪市场规模达24亿美元。 IMARC集团预测,到2034年,该市场规模将达到33亿美元,2026年至2034年的复合年增长率为3.33%。推动该市场稳定成长的因素包括:生活方式改变和环境因素导致癌症发病率上升、技术进步提高了影像品质、效率和病患安全性,以及人口老化。
癌症患者数量增加
全球癌症发生率的不断攀升推动了PET-CT扫描仪市场的成长。 PET-CT扫描仪在癌症诊断、分期和治疗过程监测中发挥着至关重要的作用。 PET-CT影像的早期检测能够提高治疗效果并改善患者预后,因此得到了广泛应用。此外,医疗专业人员越来越依赖PET- 电脑断层扫描来进行精准的疾病表征和製定个人化的治疗方案。这些扫描利用癌细胞选择性吸收的放射性药物来视觉化肿瘤内的代谢活动。同时, 电脑断层扫描提供详细的解剖影像,有助于准确识别PET检测到的异常代谢活动。 PET- 电脑断层扫描获得的全面资讯有助于肿瘤科医师就治疗策略(包括手术、放射线治疗、化疗和标靶治疗)做出明智的决策。此外,PET- 电脑断层扫描还可以加快治疗的启动速度,从而潜在地改善患者的预后。在对抗癌症的斗争中,提高先进诊断工具的可及性至关重要。
技术进步
PET-CT扫描仪的创新有助于提高影像品质、效率和病患安全性。最新的PET-CT扫描仪具有更高的空间分辨率,能够更清晰地显示微小病灶,并提高肿瘤检测和定性的准确性。这项进步使得早期诊断和更精准的治疗方案製定成为可能。此外,先进的PET-CT扫描仪缩短了扫描时间,最大限度地减少了患者的不适感,并简化了医疗机构的工作流程。快速影像撷取使临床医生能够在有限的时间内进行更多扫描,从而提高了患者处理能力和资源利用效率。此外,PET-CT技术的进步正推动着新型扫描仪的研发,这些扫描仪能够在保持诊断影像品质的同时降低辐射曝射量。这些扫描仪透过最大限度地减少患者的辐射暴露,并降低重复影像检查带来的长期不良反应风险,从而提高了安全性。此外,采用呼吸门控和运动追踪等先进运动校正技术的PET-CT扫描器可确保获得更清晰、无伪影的影像。
老年人口增加
全球人口老化加剧,推动了对PET-CT扫描仪的需求,对市场产生了正面影响。老年人更容易罹患癌症、阿兹海默症、心血管疾病和其他慢性疾病,因此需要能够准确检测和监测这些疾病的先进设备。 PET-CT扫描仪可对心臟功能、心肌灌注和心肌活力进行全面评估,从而支持老年患者心血管疾病的诊断和治疗。此外,老龄化与神经退化性疾病风险增加有关。 PET-CT成像能够提供有关脑部代谢、淀粉样蛋白沉积和神经传导物质结合的重要讯息,有助于老年人疾病的早期诊断和监测。此外,老年患者通常合併多种疾病,需要进行全面的诊断评估。 PET-CT扫描仪具有多模态影像功能,可在单次扫描中同时评估多个器官系统。这种综合方法简化了诊断流程,并有助于临床医生更好地管理老年人复杂的健康状况。
The global PET-CT scanner device market size reached USD 2.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 3.33 % during 2026-2034. The market is experiencing stable growth driven by rising prevalence of cancer due to lifestyle changes and environmental factors, increasing technological innovations that are leading to enhanced imaging quality, efficiency, and patient safety, and the growing geriatric population.
Rising prevalence of cancer cases
The increasing prevalence of cancer among the masses around the world is propelling the PET-CT scanner device market growth. PET-CT scanners play a pivotal role in cancer diagnosis, staging, and treatment monitoring. Early detection through PET-CT imaging enhances treatment efficacy and patient outcomes, contributing to its widespread adoption. Moreover, healthcare providers are increasingly relying on PET-CT scans for accurate disease characterization and personalized treatment planning. These scans utilize radiopharmaceuticals that are selectively taken up by cancer cells, allowing for the visualization of metabolic activity within tumors. Meanwhile, CT scans provide detailed anatomical images that help precisely locate abnormal metabolic activity detected by PET. The comprehensive information obtained from PET-CT scans aids oncologists in making informed decisions regarding treatment strategies, including surgery, radiation therapy, chemotherapy, and targeted therapies. In addition, PET-CT scans enable prompt initiation of treatment and potentially improve patient outcomes. There is a rise in the need for improved access to advanced diagnostic tools to fight against cancer.
Technological advancements
Innovations in PET-CT scanners assist in enhancing imaging quality, efficiency, and patient safety. Modern PET-CT scanners feature higher spatial resolution that allows for clearer visualization of small lesions and improved accuracy in tumor detection and characterization. This advancement enables earlier diagnosis and more precise treatment planning. Moreover, advanced PET-CT scanners offer shorter scan times that benefit in reducing patient discomfort and enhancing workflow efficiency in healthcare settings. Rapid image acquisition enables clinicians to perform more scans in a time frame, leading to increased patient throughput and improved resource utilization. Furthermore, advancements in PET-CT technology are leading to the development of scanners with lower radiation doses while maintaining diagnostic image quality. These scanners improve safety and reduce the risk of long-term adverse effects associated with repeated imaging studies by minimizing radiation exposure to patients. Apart from this, PET-CT scanners employed with advanced motion correction techniques, such as respiratory gating and motion tracking, ensure sharper and artifact-free images.
Increasing geriatric population
The growing demand for PET-CT scanner devices due to rising geriatric population worldwide is positively influencing the market. Elderly individuals are more susceptible to cancer, Alzheimer's disease, cardiovascular disorders, and other chronic diseases, necessitating advanced devices that detect and monitor diseases accurately. PET-CT scanners enable comprehensive assessment of cardiac function, myocardial perfusion, and viability, aiding in the diagnosis and management of cardiovascular conditions in geriatric patients. Moreover, aging is associated with an increased risk of neurodegenerative disorders. PET-CT imaging provides valuable insights into brain metabolism, amyloid deposition, and neuroreceptor binding that facilitate early diagnosis and disease monitoring in elderly individuals. Apart from this, geriatric patients often have multiple comorbidities, requiring comprehensive diagnostic evaluations. PET-CT scanners offer multimodal imaging capabilities, allowing for simultaneous assessment of multiple organ systems in a single examination. This integrated approach benefits in streamlining diagnostic workflows and enhancing clinical decision-making in managing complex health conditions in the elderly.
Stationary scanners account for the majority of the market share
Stationary scanners are large and fixed imaging systems that are usually found in hospitals, imaging centers, and academic institutions. They are designed to provide high-resolution imaging for a wide range of applications, including oncology, cardiology, and neurology. They offer superior image quality and diagnostic accuracy. They have comprehensive anatomical and functional imaging capabilities.
Portable scanners/mobile scanners are compact and mobile imaging systems designed for flexible deployment in various clinical settings, including intensive care units (ICUs), operating rooms, and remote locations. They offer on-site imaging capabilities, enabling POC diagnostics and intraoperative imaging during surgical procedures. They are compact and have a lightweight design for easy transportation.
Medium slice scanner (64 slices) holds the largest market share
Medium slice scanner (64 slices) offers enhanced imaging capabilities as compared to low slice scanners and provide higher image resolution, faster scan times, and improved diagnostic accuracy. It is commonly used in larger hospitals, imaging centers, and academic institutions for a wide range of clinical applications. It is suitable for precise tumor localization, staging, and treatment planning. It assists in providing improved image quality and diagnostic accuracy.
Low slice scanner (<64 slices) is suitable for basic imaging applications and commonly found in smaller healthcare facilities, clinics, and outpatient centers where lower throughput and image quality suffice for routine diagnostic purposes. It has basic imaging capabilities for routine diagnostic studies. It is economical and has a space-efficient design suitable for smaller healthcare settings.
High slice scanner (>64 slices) offers advanced imaging performance with ultra-high spatial resolution, rapid scan speeds, and advanced clinical applications. It is used in advanced medical centers, research institutions, and specialized healthcare facilities for demanding imaging studies. It has advanced imaging capabilities for complex clinical and research applications.
Flurodeoxyglucose (FDG) represents the leading market segment
Flurodeoxyglucose (FDG) is commonly used radiotracer in PET imaging. It consists of a glucose molecule labeled with a positron-emitting fluorine-18 (^18F) isotope. FDG is taken up by cells in proportion to their metabolic activity, making it a valuable tool for detecting areas of increased glucose metabolism, such as cancerous tumors. It evaluates brain metabolism and detects various neurodegenerative diseases.
62Cu ATSM is a radiotracer used in PET imaging to assess tissue oxygenation. It selectively accumulates in hypoxic regions of tissues, making it useful for identifying areas of poor oxygenation within tumors. 62Cu ATSM PET imaging has potential applications in oncology for predicting tumor response to therapies and guiding treatment decisions.
FMISO is a radiotracer used in PET imaging to assess tissue hypoxia. It penetrates cell membranes and becomes trapped in hypoxic cells due to reduced oxygen availability. FMISO PET imaging enables visualization and quantification of tissue hypoxia, which is associated with tumor aggressiveness, resistance to therapy, and poor patient outcomes.
Gallium-based radiotracers, such as Ga-DOTA peptides and Ga-PSMA, are used in PET imaging for various clinical applications. Ga-DOTA peptides target somatostatin receptors and are employed in neuroendocrine tumor imaging, while Ga-PSMA targets prostate-specific membrane antigen and is used in prostate cancer imaging.
Hospitals exhibit a clear dominance in the market
Hospitals are healthcare institutions that provide a wide range of medical services, including diagnostic imaging. Hospital-based imaging departments offer comprehensive imaging services to inpatients and outpatients and serve a diverse patient population across various medical specialties and clinical settings. It has multidisciplinary teams of healthcare professionals, including radiologists, oncologists, and nuclear medicine physicians.
Diagnostic centers, also known as imaging centers or medical imaging facilities, specialize in providing diagnostic imaging services to patients referred by healthcare providers. These centers focus on diagnostic imaging and offer a range of imaging modalities, including PET-CT scanners, in outpatient settings. They focus on outpatient care, with no inpatient services provided.
Research institutes are academic or independent organizations dedicated to scientific research and innovation. They have advanced imaging technologies, including PET-CT scanners, to support preclinical and clinical research studies across various disciplines. They focus on scientific research and innovation in specific fields of study.
Oncology dominates the market share
In oncology, PET-CT imaging plays a critical role in the diagnosis, staging, treatment planning, and monitoring of various types of cancers. PET-CT scans help oncologists visualize metabolic activity within tumors, assess tumor characteristics, detect metastases, and evaluate treatment response. These scanners are beneficial in diagnosing and staging cancers, including lung cancer, breast cancer, colorectal cancer, and lymphoma. They are beneficial in early detection of tumors and metastases for timely intervention.
In neurology, PET-CT imaging is utilized to evaluate brain metabolism, assess neurodegenerative diseases, detect brain tumors, and investigate neurological disorders. PET-CT scans provide valuable insights into brain function, neurotransmitter activity, and cerebral blood flow, aiding in the diagnosis and management of various neurological conditions.
In cardiology, PET-CT imaging is used to assess myocardial perfusion, viability, and function, and to detect and characterize coronary artery disease and other cardiac abnormalities. PET-CT scans provide detailed anatomical and functional information, enabling cardiologists to diagnose cardiac conditions, evaluate treatment options, and assess prognosis.
Asia Pacific leads the market, accounting for the largest PET-CT scanner device market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific accounted for the largest market share due to the presence of well-established new hospitals, diagnostic centers, and specialty clinics. In addition, the rising prevalence of cancer among individuals in the region is bolstering the market growth.
North America stands as another key region in the market, driven by the increasing awareness among individuals about the benefits of early disease detection. Besides this, North America is a hub for technological innovation in healthcare, with leading manufacturers and research institutions continuously developing advanced PET-CT scanner devices.
Europe maintains a strong presence in the market, with the rising focus on improving patient care. Additionally, stringent regulatory standards ensure the safety and efficacy of PET-CT scanner devices, which is impelling the market growth.
Latin America exhibits the growing potential in the market on account of the improving healthcare infrastructure. In addition, the growing demand for advanced care among patients is offering a positive market outlook.
The Middle East and Africa region is primarily driven by the thriving medical tourism. Furthermore, partnerships between local healthcare providers, international medical device manufacturers, and research institutions are facilitating technology transfer and knowledge sharing relayed to PET-CT scanners.
Key players are investing in R&D activities to develop innovative PET-CT scanner technologies with improved imaging capabilities, enhanced diagnostic accuracy, and patient comfort. They are exploring new radiotracers and imaging agents to expand the applications of PET-CT scans in oncology, neurology, cardiology, and other medical specialties. Additionally, they are incorporating advanced technologies to automate image analysis, optimize workflows, and improve diagnostic efficiency. Besides this, major manufacturers are introducing next-generation PET-CT scanner models with advanced features, such as higher image resolution, faster scan times, reduced radiation doses, and enhanced software functionalities. They are also developing compact and mobile PET-CT scanners to improve accessibility and flexibility in various clinical settings, including hospitals, clinics, and remote locations.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include: